transcript
show notes
There is a profound shift in the longevity field as it transitions from speculative science to clinical application and professional accountability. A major focus is the FDA clearance and initiation of the first human trials for ER-100, an epigenetic reprogramming therapy designed to restore youthful cellular function in patients with vision loss. Concurrent with these medical milestones, the community is grappling with a leadership crisis involving Dr. David Sinclair, who resigned from a top research position following criticism over his "age reversal" marketing and commercial interests. This also highlights an epistemological rift between researchers seeking to classify aging as a disease and those who view it as a natural biological process. Furthermore, this details the rigorous validation of anti-aging compounds like rapamycin and metformin, contrasting evidence-based research against the proliferation of unproven supplements. Together, this illustrates a sector striving for scientific credibility and regulatory clarity amidst high-stakes commercial pressure.
